Improving quality of life in metastatic castration-resistant prostate cancer: the role of androgen receptor axis-targeted agents

Androgen receptor axis-targeted agents (ARTAs), specifically enzalutamide and abiraterone acetate, have significantly extended the survival of men with metastatic castration-resistant prostate cancer (mCRPC), making them the standard of care for mCRPC. In addition, the impact of both drugs on the...

Full description

Bibliographic Details

Published in:	Journal of Men's Health
Main Authors:	Monika Kuzma, Mária Breznická, Ján Kliment
Format:	Article
Language:	English
Published:	MRE Press 2023-07-01
Subjects:	quality of life abiraterone enzalutamide castration-resistant prostate cancer
Online Access:	https://oss.jomh.org/files/article/20230731-44/pdf/JOMH2023012001.pdf